Abstract

Despite significant strides made in understanding the pathophysiology of high-grade gliomas over the past two decades, most patients succumb to these neoplasias within two years of diagnosis. Furthermore, there are various co-morbidities associated with glioma and standard of care treatments. Emerging evidence suggests that aberrant glutamate secretion in the glioma microenvironment promotes tumor progression and contributes to the development of co-morbidities, such as cognitive defects, epilepsy, and widespread neurodegeneration. Recent data clearly illustrate that neurons directly synapse onto glioma cells and drive their proliferation and spread via glutamatergic action. Microglia are central nervous system-resident myeloid cells, modulate glioma growth, and possess the capacity to prune synapses and encourage synapse formation. However, current literature has yet to investigate the potential role of microglia in shaping synapse formation between neurons and glioma cells. Herein, we present the literature concerning glutamate’s role in glioma progression, involving hyperexcitability and excitotoxic cell death of peritumoral neurons and stimulation of glioma proliferation and invasion. Furthermore, we discuss instances in which microglia are more likely to sculpt or encourage synapse formation during glioma treatment and propose studies to delineate the role of microglia in synapse formation between neurons and glioma cells. The sex-dependent oncogenic or oncolytic actions of microglia and myeloid cells, in general, are considered in addition to the functional differences between microglia and macrophages in tumor progression. We also put forth tractable methods to safely perturb aberrant glutamatergic action in the tumor microenvironment without significantly increasing the toxicities of the standard of care therapies for glioma therapy.

Highlights

  • Gliomas are the most prevalent primary malignant tumor type of the central nervous system (CNS), constituting more than 80% of malignant CNS tumors in the United States [1]

  • Mounting evidence supports a role for glutamate in the progression of glioma and for the genesis of multiple co-morbidities that are difficult to manage in the clinical setting

  • Hyperexcitability and excitotoxicity of peritumoral neurons coupled with the activation of glutamate on glioma cells emerge as critical processes for the growth and spread of glioma cells

Read more

Summary

Introduction

Gliomas are the most prevalent primary malignant tumor type of the central nervous system (CNS), constituting more than 80% of malignant CNS tumors in the United States [1]. A series of sophisticated studies have described the biophysical basis for the pro-tumorigenic interactions between glioma cells and peritumoral neurons [17,18] These studies have expanded upon our understanding of biophysical interactions between neurons and glioma cells, namely that neurons synapses onto glioma cells and fuel their growth via the activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors on glioma cells [17,18]. This de novo synaptic input generates coordinated calcium transients that spread to glioma cells connected via tumor microtubes (TMs) [19] and results in a calcium-dependent increase in glioma invasiveness and growth. We hope to lend credit to the hypothesis that immunomodulation may prove effective in curbing oncogenic interactions between neurons and glioma cells

Pathophysiological Hallmarks of Aberrant Glutamate Secretion
GABAergic Signaling in the Glioma Microenvironment
Aberrant Communication between Glioma Cells and Peritumoral Neurons
Context-Dependent Actions on Synapse Formation and Pruning
Pilot Studies to Discern the Role of Synapse Formation and Maintenance
Sex-Specific Microglial Modulation of Glioma Progression
Microglia and Macrophages
Pharmacological Targeting of Aberrant Glutamatergic Action in Glioma
Targeting Myeloid Cells during Glioma Treatment
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call